The Claim
In women with cystic fibrosis, obesity, and diabetes, 12 months of semaglutide therapy resulted in improved glycemic control (HbA1c reduction to target levels) and a 14.8% reduction in body weight, despite concurrent musculoskeletal decline.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In women with cystic fibrosis, obesity, and diabetes, taking semaglutide for 12 months lowered blood sugar to target levels and reduced body weight by 14.8%, while muscle and bone health worsened.
See the scientific wording
In a woman with cystic fibrosis, obesity, and diabetes, semaglutide therapy improved glycemic control (HbA1c from 10.1% to target levels) and reduced body weight by 14.8% over 12 months, demonstrating metabolic benefit despite concurrent musculoskeletal decline.
A drug that mimics a gut hormone reduces hunger and food intake, causing the body to burn more energy than it takes in. This forces the body to break down muscle and fat for fuel, which lowers blood sugar and weight. At the same time, less body weight means less stress on bones, and fewer fat cells mean fewer signals that help build bone and muscle, leading to weaker muscles and fragile bones.
What the research says
1 studySemaglutide helped this woman with cystic fibrosis, obesity, and diabetes lower her blood sugar and lose nearly 15% of her weight — just like the claim says. But it also made her muscles weaker and bones more fragile, which is a downside.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.